Validus Cellular Therapeutics

World's first antibacterial cell therapy to treat u...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Validus Cellular Therapeutics:
Fast Facts

Validus is developing the world’s first cell therapy-based treatment to address antibiotic-resistant infections of which 2.8 million people in the US are affected by annually.

Our approach uses allogeneic antibacterial cell therapy to attack infections, stimulating the body’s natural healing to resolve untreatable infections.

Increasingly Resistant
Bacterial Infection

Infectious diseases are becoming increasingly untreatable as a result of antibiotic resistance, leading to more widespread and severe instances of infection.

For example, there are now more than 2.8 million antimicrobial resistant infections across the US annually, and approximately 35,000 people die annually as a result.

Treatment options for these types of infections are limited as we are now in a post-antibiotic era. Existing alternatives involve more extreme measures such as revision surgery, high-dose last alternative antibiotics, or amputation.

There is a significant and urgent need for a novel, 21st century, approach to treating infections that goes beyond our reliance on antibiotics.


Therapies Beyond Antibiotics

Validus is developing a novel approach to treating antibiotic-resistant infections that leverages cell therapy to attack resistant bacteria and facilitate the body’s own healing processes.

Our solution is an IV-infused, allogeneic antibacterial cell therapy that works in tandem with antibiotic administration to treat untreatable infections.

Early animal trials of our technology resulted in 87% of infections fully-resolved or significantly improved.

Our technology therefore addresses the need for a therapy capable of targeting antibiotic-resistant infections and has the potential to prevent countless amputations, expensive antibiotic treatments and ~35K deaths annually.

Enabling a Natural Response

Validus addresses the need for readily-implemented therapies to treat antibiotic-resistant infections with our on-demand cellular therapy product, VCT-101: the world’s first antibacterial cell therapy.

The mechanism of action behind VCT-101 trains Mesenchymal Stromal Cells (MSCs) to recognize bacterial infection and trigger natural immune mechanisms to fight it.

Using a proprietary process and activating agent, Validus directs MSCs to migrate to sites of inflammation, produce antimicrobial immune effectors and stimulate wound healing.

Not only is VCT-101 active against biofilm, a particularly resistant state of bacterial growth, but it is active against tested drug-resistant bacterial pathogens, including polymicrobial infections.

Accomplishments & Strategic Partners

Validus Executive Team

Ethan Mann, PhD, MBA, FOUNDER AND CEO | Ethan has extensive experience leading medical technology commercialization efforts, including an exit with his previous venture, Sharklet Technologies, Inc. He has raised numerous rounds of capital for ventures, including developing access to non-dilutive capital.

Steven Dow, DVM, PhD, FOUNDER AND CTO | Dr. Dow is a prolific inventor and has pioneered the development of our antibacterial cell therapy in animal model studies.

David Desmond, MBA, CFO | David has extensive leadership experience with startups and large corporations, structured debt and equity financing.

Doug Looker, PhD, VP OF OPERATIONS | Doug is a pharmaceutical industry veteran having launched multiple drug products with preclinical and regulatory operations roles, including several in the field of infectious disease.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.